Business
PDS Biotech Announces Two Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology Annual Meeting
Preliminary efficacy and safety update on PDS0101 in combination with KEYTRUDA® (pembrolizumab) in first-line recurrent or metastatic HPV-positive head and
About this update from Pds Biotechnology Corporation
[{"type":"text","content":"Preliminary efficacy and safety update on PDS0101 in combination with KEYTRUDA® (pembrolizumab) in first-line recurrent or metastatic HPV-positive head and neck cancerPreliminary efficacy and safety update by NCI on PDS0101-based triple combination in advanced refractory HPV-associated cancers FLORHAM PARK, N.J., April 27, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technologies, today announced the titles of two abstracts accepted for poster presentations during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting being held from June 3-7, 2022. Abstract # 6041 poster presentation summarizes updates to the preliminary efficacy and safety data from the PDS Biotechnology sponsored VERSATILE-002 Phase 2 clinical trial, which is studying PDS0101 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for the treatment of recurrent or metastatic HPV16-positive head and neck cancer. This trial is designed to treat both checkpoint inhibitor (CPI) naïve and refractory patients. PDS Biotech previously announced that the trial had achieved its preliminary efficacy milestone in the CPI naive arm earlier this year and presented detailed preliminary safety data at the 2022 Multidisciplinary Head and Neck Cancers Symposium. Abstract Number: 6041 Abstract Title: PDS0101 a novel type 1 interferon and CD8+ T-cell activating immunotherapy in combination with pembrolizumab in subjects with recurrent/metastatic HPV16-positive head and neck squamous cell carcinoma (HNSCC).Presenting Author: Jared Weiss, M.D., Section Chief of Thoracic and Head and Neck Oncology at the University of North Carolina at Chapel Hill School of Medicine and Lineberger Comprehensive Cancer Center, who serves as the Lead Principal Investigator for VERSATILE-002Session Title: Head and Neck CancerSession Date and Time: Monday, June 6, 2022, 1:15 PM-4:15 PM CDT Abstract # 2518 poster discussion presentation summarizes findings from the ongoing National Cancer Institute (NCI)-led Phase 2 clinical trial, which studies PDS0101 in combination with two investigational immune-modulating agents. This ...